Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App




Fatty Acid Levels Could Help Predict Psychosis Risk

By HospiMedica International staff writers
Posted on 03 Nov 2016
A novel probabilistic model that combines history, clinical assessment, and fatty-acid biomarkers could help predict transition to first-episode psychosis, claims a new study.

Researchers at the University of Adelaide (UA; Australia), the Medical University of Vienna (Austria), and other institutions conducted a study in 40 patients in Austria to explore if a probabilistic model that combine medical historical, clinical risk factors, oxidative stress and cell membrane fatty acids biomarkers, and resting quantitative electroencephalography (qEEG), could improve the identification of patients with ultra-high risk (UHR) of psychosis.

The researchers then analyzed concurrent and baseline data of the study cohort, who overall exhibited a 28% one-year transition rate to psychosis. They then clustered several significant variables into historical (history of drug use), clinical (Positive and Negative Symptoms Scale [PNSS] and Global Assessment of Function [GAF] scores), and biomarker (total omega-3, nervonic acid) groups, and calculated the post-test probability of transition for each group separately and for group combinations, using the odds ratio form of Bayes’ rule.

The results showed that the combination of all three variable groups vastly improved the specificity of prediction. The model identified over 70% of UHR patients who transitioned within one year, compared with 28% identified by standard UHR criteria. The model classified 77% of cases as very high or low risk based on history and clinical assessment, suggesting that a staged approach, which reserved fatty-acid markers for 23% of cases remaining at intermediate probability following bedside interview, could be the most efficient. The study was published on September 20, 2016, in the Translational Psychiatry.

“Currently, all patients in the ultra-high risk group are considered to have a similar chance of a future psychotic episode; however, we have been able to identify high, intermediate and low-risk groups. The model may help clinicians to decide when a patient's risk of psychosis outweighs any side effects of treatment,” said lead author psychiatrist Scott Clark, MD, of the University of Adelaide. “Fatty acids such as omega-3 and nervonic acid are critical for the normal functioning of the brain, and low levels have been associated with the development of psychosis in high-risk groups.”

The concept of clinical UHR for psychosis was developed to facilitate early detection and intervention, and is defined by a cluster of subthreshold psychotic symptoms. These can include perceptions, such as hallucinations; thinking - for example, ideas of reference, odd beliefs, or magical thinking; and trait risk factors like a family history of psychosis. These are accompanied by impairment in day-to-day function. In recent meta-analysis, studies show that less than 30% of UHR patients will have transitioned to psychosis three years after identification.

Related Links:
University of Adelaide
Medical University of Vienna

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Cylindrical Water Scanning System
SunSCAN 3D
New
Needle-Free IV Connector Technology
Clave
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Trilogy Valve with locator technology is the only TAVI system approved for aortic regurgitation (Photo courtesy of JenaValve)

New Transcatheter Valve Found Safe and Effective for Treating Aortic Regurgitation

Aortic regurgitation is a condition in which the aortic valve does not close properly, allowing blood to flow backward into the left ventricle. This results in decreased blood flow from the heart to the... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.